MingMed

Software development builds systems or system components based on user requirements through stages including requirements capture, analysis, design, implementation, and testing.

Yinming Bio is a Chinese company focused on developing innovative drugs with global competitiveness, supported by a team of top scientists and experts.

MingMed Biotechnology reports positive Phase II trial results for its oral drug **QA102**, targeting **intermediate age-related macular degeneration (AMD)**. The data was presented at the **Association for Research in Vision and Ophthalmology (ARVO) 2026** conference. QA102 is part of the company’s pipeline of novel therapeutics for retinal diseases.

May 2026PR NewswireNews article

Claruvis Pharmaceutical secures China’s first marketing approval for **Retoxin®**, a recombinant botulinum toxin type A (project code **YY001**). The drug targets temporary improvement of moderate-to-severe glabellar lines in adult patients. This approval marks a technological milestone in biopharmaceuticals, leveraging recombinant DNA techniques to produce the toxin.

Apr 2026BioSpaceNews article

MingMed is pursuing a Hong Kong stock exchange listing to secure capital for expanding its research operations. The company plans to establish an incubation center at the Hong Kong Science and Technology Park in the third quarter of 2024, aiming to accelerate development of its Botox alternative.

Jun 2025South China Morning PostNews article

MingMed Biotech, a Chinese biotech firm, is pursuing an initial public offering (IPO) despite generating no revenue. The company follows a growing trend of pre-IPO drug startups raising capital through public listings without proven commercial success.

Aug 2022Bamboo WorksNews article